ArticleJournal of pharmaceutical health care and sciences2025
Impact of a tailored, department-specific antimicrobial stewardship team intervention based on AWaRe guidelines: a single-center, cohort, interrupted-time series study.
Article in Journal of pharmaceutical health care and sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThe global crisis of antimicrobial resistance (AMR) necessitates robust antimicrobial stewardship. The World Health Organization's (WHO) Access, Watch, Reserve (AWaRe) classification is a key tool for guiding antibiotic prescribing to combat AMR. The WHO's global target was to have at least 60% of antibiotic consumption fall into the Access category by 2023. This study evaluated the effectiveness of localized interventions toward this goal.
methodsThis retrospective, longitudinal study analyzed oral outpatient antibiotic prescriptions at Kochi Medical School Hospital from April 2022 to June 2025. Data included defined daily doses (DDDs), days of therapy (DOTs), and AWaRe classifications. Based on a preceding analysis, the antimicrobial stewardship team (AST) implemented targeted, department-specific educational interventions starting in April 2024. The impact was evaluated using seasonally adjusted time-series analysis and regression models. The study also included a survey of Escherichia coli susceptibility to levofloxacin, ciprofloxacin, and sulfamethoxazole/trimethoprim from outpatient urinary isolates.
resultsThe AST intervention led to a statistically significant increase in the usage proportion and DDDs of Access antibiotics (+ 2.92%, p = 0.005 and + 376.5 DDDs, p = 0.001, respectively), with a corresponding decrease in Watch antibiotics (-3.00%, p = 0.003). However, DOTs did not significantly change, indicating the intervention primarily impacted drug choice, not treatment duration. Top prescribed agents were clarithromycin (24.2%), sulfamethoxazole/trimethoprim (20.7%), and rifaximin (10.7%). E. coli susceptibility to levofloxacin and ciprofloxacin was low (< 80% overall), particularly in extended-spectrum β-lactamase (ESBL)-producing strains (~ 10%). Sulfamethoxazole/trimethoprim susceptibility remained high overall (≥ 80%) but was low (< 80%) for ESBL-producing strains.
conclusionsAST interventions successfully shifted outpatient prescribing from Watch to Access antibiotics, demonstrating that targeted interventions can modify prescribing behavior. However, challenges remain, such as addressing treatment duration and achieving broader goals. The observed resistance patterns highlight the critical need for prescribers to consult local antibiograms. Future strategies require a more comprehensive approach, including real-time alerts and improved diagnostics, to further optimize antibiotic use and combat AMR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.